FDA Issues Warning Letters To Companies Unlawfully Selling CBD Products to Treat Medical Conditions

The United States FDA (Food and Drug Administration) has issued notices to 2 firms for illicitly retailing products containing CBD in ways that contravene the Federal Food, Drug and Cosmetic Act. FDA is taking the aforementioned measures as a continuation of efforts to chase businesses that unlawfully market CBD products with bogus assertions that they can treat medical situations.

The Principal Deputy Commissioner of FDA, Amy Abernethy mentioned,

“CBD has not been shown to treat opioid addiction. Opioid addiction is a real problem in our country, and those who are addicted need to seek out proper treatment from a health care provider. There are many unanswered questions about the science, safety, effectiveness and quality of unapproved products containing CBD.”

It is to be noted that any product proposed to treat an ailment has a therapeutic or medical use, under the Federal Food, Drug and Cosmetic Act. Furthermore, any product that is planned to disturb the construction or function of a human or animal body, has to be considered as a drug. Particularly, the Food and Drug Administration has not permitted any CBD products other than one prescription human drug product to treat infrequent and critical classes of epilepsy.